Literature DB >> 26957335

Cardiovascular diseases among patients with schizophrenia.

Muhammad Chanchal Azad1, Wendy Diana Shoesmith1, Mohammad Al Mamun2, Ahmad Faris Abdullah1, Daw Khin Saw Naing1, Mahadasa Phanindranath3, Tanvir Chowdhury Turin4.   

Abstract

The presence of comorbid physical illnesses especially, cardiovascular diseases (CVD) in schizophrenia is a growing area of concern in recent years. In order to reduce disease burden, to improve quality of life and to provide holistic care, it is important to know about the relationship between schizophrenia and CVD. The objective of this review is to explore the extent of CVD problems, relevant risk factors and potential measures for early diagnosis and prevention of CVD among patients with schizophrenia. Worldwide studies show that patients with schizophrenia have a higher mortality and lower life expectancy than the general population. CVD is the leading cause of increased mortality in schizophrenia. Common CVD risk factors in schizophrenia include metabolic syndrome, sedentary behaviour, tobacco smoking, effects of antipsychotics, long chain omega-3 fatty acid deficiency and shared genetics between CVD and schizophrenia. The potential methods for early detection and prevention of CVD in schizophrenia are also discussed. Though the patients with schizophrenia form a high risk group for CVD, consensus guidelines for early detection and prevention of CVD in schizophrenia are lacking. Comorbidity of CVD in schizophrenia needs more serious attention by clinicians and researchers.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular diseases; Early detection; Prevention; Risk factors; Schizophrenia

Mesh:

Year:  2015        PMID: 26957335     DOI: 10.1016/j.ajp.2015.11.012

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  9 in total

Review 1.  Nutritional Factors Affecting Mental Health.

Authors:  So Young Lim; Eun Jin Kim; Arang Kim; Hee Jae Lee; Hyun Jin Choi; Soo Jin Yang
Journal:  Clin Nutr Res       Date:  2016-07-26

2.  Treatment following myocardial infarction in patients with schizophrenia.

Authors:  Rubina Attar; Martin Berg Johansen; Jan Brink Valentin; Jørgen Aagaard; Svend Eggert Jensen
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

3.  Serum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study.

Authors:  X Yang; L Sun; A Zhao; X Hu; Y Qing; J Jiang; C Yang; T Xu; P Wang; J Liu; J Zhang; L He; W Jia; C Wan
Journal:  Transl Psychiatry       Date:  2017-07-25       Impact factor: 6.222

Review 4.  The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.

Authors:  Cynthia Yi-An Chen; Kah Kheng Goh; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Front Psychiatry       Date:  2021-01-20       Impact factor: 4.157

5.  Experiences of Hospitalization of Patients With Psychotic Disorders on Medical-Surgical Units: A Thematic Analysis.

Authors:  Guy M Weissinger; J Margo Brooks Carthon; Charisse Ahmed; Bridgette M Brawner
Journal:  J Am Psychiatr Nurses Assoc       Date:  2019-12-03       Impact factor: 2.056

Review 6.  Systematic Review of Epigenetic Effects of Pharmacological Agents for Bipolar Disorders.

Authors:  Laura E Lockwood; Nagy A Youssef
Journal:  Brain Sci       Date:  2017-11-18

Review 7.  Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?

Authors:  Estefania Gastaldello Moreira; Karine Maria Boll; Dalmo Guilherme Correia; Janaina Favaro Soares; Camila Rigobello; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

8.  Schizophrenia and Hospital Admissions for Cardiovascular Events in a Large Population: The APNA Study.

Authors:  Sara Guillen-Aguinaga; Antonio Brugos-Larumbe; Laura Guillen-Aguinaga; Felipe Ortuño; Francisco Guillen-Grima; Luis Forga; Ines Aguinaga-Ontoso
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-13

9.  Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.

Authors:  Christoph U Correll; Michael Tocco; Jay Hsu; Robert Goldman; Andrei Pikalov
Journal:  Eur Psychiatry       Date:  2022-03-24       Impact factor: 7.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.